Chapter II
Neoplasms
(C00-D48)

Rules Conventions GCS DChS.II.1 DChS.II.2 DChS.II.4 Guidance

Malignant neoplasms
(C00-C97)

Coding-Hint
Use additional code ( U85) , if desired, to identify resistance, non-responsiveness and refractive properties of the neoplasm to antineoplastic drugs.

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
(C00-C75)

Malignant neoplasms of thyroid and other endocrine glands
(C73-C75)

C73 Malignant neoplasm of thyroid gland
Comorbidity DCS.II.1 DCS.II.3 DCS.II.5 DCS.XIII.4

C74 Malignant neoplasm of adrenal gland
Comorbidity DCS.II.1 DCS.II.3 DCS.II.5 DCS.XIII.4

C74.0 Cortex of adrenal gland
C74.1 Medulla of adrenal gland
C74.9 Adrenal gland, unspecified

C75 Malignant neoplasm of other endocrine glands and related structures
Comorbidity DCS.II.1 DCS.II.3 DCS.II.5 DCS.XIII.4

Excl.:
adrenal gland ( C74.-)
endocrine pancreas ( C25.4)
ovary ( C56)
testis ( C62.-)
thymus ( C37)
thyroid gland ( C73)
C75.0 Parathyroid gland
C75.1 Pituitary gland
C75.2 Craniopharyngeal duct
C75.3 Pineal gland
C75.4 Carotid body
C75.5 Aortic body and other paraganglia
C75.8 Pluriglandular involvement, unspecified
Note:

If the sites of multiple involvement are known, they should be coded separately.

C75.9 Endocrine gland, unspecified